- Home
- AGI vs BMRN Comparison
AGI vs BMRN Comparison
Compare AGI & BMRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AGI
- BMRN
- Stock Information
- Founded
- AGI 2003
- BMRN 1996
- Country
- AGI Canada
- BMRN United States
- Employees
- AGI N/A
- BMRN N/A
- Industry
- AGI Precious Metals
- BMRN Biotechnology: Pharmaceutical Preparations
- Sector
- AGI Basic Materials
- BMRN Health Care
- Exchange
- AGI Nasdaq
- BMRN Nasdaq
- Market Cap
- AGI 10.9B
- BMRN 11.3B
- IPO Year
- AGI 1999
- BMRN 1999
- Fundamental
- Price
- AGI $28.40
- BMRN $58.58
- Analyst Decision
- AGI Buy
- BMRN Buy
- Analyst Count
- AGI 4
- BMRN 23
- Target Price
- AGI $30.38
- BMRN $93.14
- AVG Volume (30 Days)
- AGI 3.5M
- BMRN 2.6M
- Earning Date
- AGI 07-30-2025
- BMRN 08-04-2025
- Dividend Yield
- AGI 0.35%
- BMRN N/A
- EPS Growth
- AGI 63.27
- BMRN 154.69
- EPS
- AGI 0.82
- BMRN 3.40
- Revenue
- AGI $1,507,900,000.00
- BMRN $3,063,608,000.00
- Revenue This Year
- AGI $34.90
- BMRN $12.34
- Revenue Next Year
- AGI $17.45
- BMRN $10.01
- P/E Ratio
- AGI $34.55
- BMRN $17.23
- Revenue Growth
- AGI 34.51
- BMRN 18.36
- 52 Week Low
- AGI $17.43
- BMRN $52.93
- 52 Week High
- AGI $31.00
- BMRN $93.04
- Technical
- Relative Strength Index (RSI)
- AGI 67.43
- BMRN 52.49
- Support Level
- AGI $25.69
- BMRN $57.16
- Resistance Level
- AGI $26.20
- BMRN $58.70
- Average True Range (ATR)
- AGI 0.78
- BMRN 1.77
- MACD
- AGI 0.27
- BMRN -0.07
- Stochastic Oscillator
- AGI 88.86
- BMRN 29.17
About AGI Alamos Gold Inc.
Alamos Gold Inc acquires, explores, and produces gold and other precious metals, and operates in two principal geographic areas: Canada and Mexico. The company has four operating segments being Young-Davidson, Island Gold and Magino mines operate in Canada, and the Mulatos mine operates in Sonora, Mexico. The company generates maximum revenue from the Mulatos mines.
About BMRN BioMarin Pharmaceutical Inc.
BioMarin is a global biotechnology company focused on developing and commercializing therapies for rare genetic diseases. BioMarin specializes in enzyme replacement therapies, gene therapies, and other advanced treatments aimed at addressing complex genetic disorders. The company has eight approved therapies for conditions including achondroplasia, phenylketonuria (PKU), hemophilia, and mucopolysaccharidosis. BioMarin has an expanding, yet relatively early-stage, pipeline of treatments in development.